SL Science Holding (NASDAQ: SLBT) has announced the publication of a peer-reviewed article in Biomedicines co-authored by SL Science leadership and clinical researchers from Taipei Medical University outlining a rigorous development framework for γδ T cell therapy in glioblastoma.
Beyond reviewing existing literature, the paper outlines the specific clinical trial designs, biological measurements, and testing conditions required to rigorously evaluate γδ T cell therapies in future human trials.
In a statement, Mr. William Wang, chairman and CEO of SL Science, commented, “Glioblastoma has repeatedly defeated therapies that looked convincing in preclinical models. The clear lesson is that progress depends on rigorous evidence generation in humans, not further laboratory speculation. This publication defines what we believe the next phase of development must look like: clinical trials designed from day one to show whether these cells reach the tumor, remain viable, and execute their therapeutic function. Translating this science into actionable clinical proof is our core focus, and our technology is advancing and evolving alongside new clinical discoveries. We intend our own programs to meet the exact standard we have set out here.”
